Thymectomy Bests Medical Therapy in Myasthenia Gravis Thymectomy Bests Medical Therapy in Myasthenia Gravis

' The trial ends an 80-year controversy'about benefits of thymectomy for patients with major myasthenia gravis but no thymus tumor, experts say.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

When the diagnosis of myasthenia gravis (MG) has been secured, the aim of management should be prompt symptom control and the induction of remission or minimal manifestations. Symptom control, with acetylcholinesterase inhibitors such as pyridostigmine, is commonly employed. This may be sufficient in mild disease. There is no single universally accepted treatment regimen. Corticosteroids are the mainstay of immunosuppressive treatment in patients with more than mild MG to induce remission. Immunosuppressive therapies, such as azathioprine are prescribed in addition to but sometimes instead of corticosteroids when backgroun...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Publication date: September 2020Source: Biomedicine &Pharmacotherapy, Volume 129Author(s): Wei Jiao, Fangyu Hu, Jinqiu Li, Jingwei Song, Jian Liang, Lanqi Li, Yafang Song, Zhiwei Chen, Qing Li, Lingling Ke
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
The objective of our study was to assess the tolerability and efficacy of rituximab use in children with refractory JMG.
Source: Pediatric Neurology - Category: Neurology Authors: Tags: Short Communication Source Type: research
AbstractThe robotic approach in the treatment of thymus diseases has been described in many papers, but few studies have compared the early outcome of patients after robotic and open transsternal procedure. Our study aims to confirm the non-inferiority of the robotic technique in terms of feasibility, safety and postoperative patient recovery compared to the open standard. This is a retrospective cohort study in which we compare 114 patients who underwent thymectomy for a thymus disease at our thoracic surgery unit. Our robotic surgery programme started in February 2012 with the treatment of mediastinal diseases. Since the...
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
Conclusion: With NIV, intubation was prevented in 7 and reintubation in 3 patients. NIV has lower incidence of complications. NIV should be tried in patients with impending MC.
Source: Neurology India - Category: Neurology Authors: Source Type: research
Publication date: Available online 3 July 2020Source: Stem Cell ResearchAuthor(s): Nidaa A. Ababneh, Ban Alkurdi, Dema Ali, Duaa Abuarqoub, Raghda Barham, Abdi T. Ryalat, Abdalla Awidi
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. Am J Ophthalmol 2019;205:99 –105.
Source: American Journal of Ophthalmology - Category: Opthalmology Tags: Corrigendum Source Type: research
Authors: Yilmaz V, Ulusoy C, Hajtovic S, Turkoglu R, Kurtuncu M, Tzartos J, Lazaridis K, Tuzun E Abstract Antigen-specific immune responses are crucially involved in both multiple sclerosis (MS) and myasthenia gravis (MG). Teriflunomide is an immunomodulatory agent approved for treatment of MS through inhibition of lymphocyte proliferation. MG associated with muscle-specific tyrosine kinase (MuSK) antibodies often manifests with a severe disease course, prompting development of effective treatment methods. To evaluate whether teriflunomide treatment may ameliorate MuSK-autoimmunity, experimental autoimmune MG (EAMG...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
Myasthenia Gravis (MG) is a chronic autoimmune disease (AID) with a prevalence of 1-2 per 10.000 [1]. The clinical hallmark is fluctuating weakness of striated muscles with antibodies directly affecting the neuromuscular junction. In approximately 85% of patients, the initial presenting symptoms are asymmetric ptosis and/or diplopia. Approximately 80% of initially ocular MG patients will develop generalized MG within two years of disease onset [2].
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: Systematic review article Source Type: research
Myasthenia gravis (MG) is the prototypical autoimmune disorder caused by specific autoantibodies at the neuromuscular junction. Broad-based immunotherapies, such as corticosteroids, azathioprine, mycophenolate, tacrolimus, and cyclosporine, have been effective in controlling symptoms of myasthenia. While being effective in a majority of MG patients many of these immunosuppressive agents are associated with long-term side effects, often intolerable for patients, and take several months to be effective. With advances in translational research and drug development capabilities, more directed therapeutic agents that can alter ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Brain | Myasthenia Gravis | Neurology | Neurosurgery